Industries > Pharma > Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

PUBLISHED: 22 March 2017
PAGES: 200
PRODUCT CODE: PHA0178
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0178 Categories: ,

The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 200-page report you will receive 89 tables and 50 figures – all unavailable elsewhere.

The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Report Scope
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027

• Submarket forecasts from 2017-2027:
 – Biologics
 – Aminosalicylates
 – Antibiotics
 – Corticosteroids
 – Immunomodulators

• Revenue forecast from 2017-2027 for 17 leading products:
 – Humira
 – Remicade
 – Lialda
 – Asacol
 – Pentasa
 – Xifaxan
 – Cimzia
 – Tysabri
 – Simponi
 – Canasa/Salofalk
 – Entyvio
 – Apriso
 – Medrol
 – Neoral
 – Entocort
 – Uceris
 – Azulfidine

Revenue forecasts from 2017-2027 for 11 countries:
 – US
 – Japan
 – Germany, France, UK, Spain and Italy (EU5)
 – Brazil, Russia, India and China (BRIC)

Discussions on research and development, including drug candidates in these classes:
 – Interleukin (IL) inhibitors
 – Cell-adhesion molecule (CAM) inhibitors
 – TNF-alpha inhibitors
 – Stem cell therapies
 – JAK inhibitors
 – Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Inflammatory Bowel Diseases Market Analysis: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

READ

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Categories